Construction and characterization of plasminogen activator inhibitor-1 mutants in which part of the active site loop is deleted

Fibrinolysis and Proteolysis

Volumn 11, Issue 5-6, 1997, Pages 265-271

  Gils, A ^a   Knockaert, I ^a   Declerck, P J ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ARTICLE; CONFORMATIONAL TRANSITION; DELETION MUTANT; ENZYME ACTIVE SITE; GENE DELETION; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN STABILITY; SITE DIRECTED MUTAGENESIS; STRUCTURE ANALYSIS;

EID: 0031474233     PISSN: 13690191     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(97)80111-7     Document Type: Article

References (46)

1. Pannekoek H, Veerman H, Lambers H, Diergaarde P, Verweij CL, Van Zonneveld AJ, Van Mourik JA. Endothelial plasminogen activator inhibitor (PAI): a new member of the serpin gene family. EMBO J 1986; 5: 2539-2544.
2. Ny T, Sawdey M, Lawrence D, Milan JL, Loskutoff DJ. Cloning and sequence of a cDNA coding for the human beta-migrating endothelial-cell-type plasminogen activator inhibitor. Proc Natl Acad Sci USA 1986; 83: 6776-6780.
3. Ginsburg D, Zeheb R, Young AY, et al. cDNA cloning of human plasminogen activator-inhibitor from endothelial cells. J Clin Invest 1986; 78: 1673-1680.
4. Andreasen PA, Riccio A, Welinder KG et al. Plasminogen activator inhibitor type 1: reactive center and amino-terminal heterogeneity determined by protein and cDNA sequencing. FEBS Lett 1986; 209: 213-218.
5. Carrell RW, Boswell DR. In: Barret AJ, Salvesen G, eds. Proteinase Inhibitors. Amsterdam: Elsevier Scientific Publishing Co 1986: 403-425.
6. 1-antitrypsin for structure and function of serpins. Biochemistry 1989; 28: 8951-8966.
7. Sprang SR. The latent tendencies of PAI-1. Trends Biochem Sci 1992; 17: 49-50.
8. Laskowski M, Kato I. Protein inhibitors of proteinases. Annu Rev Biochem 1980; 49: 593-626.
9. Lindahl TL, Ohlsson PI, Wiman B. The mechanism of the reaction between human plasminogen activator inhibitor-1 and tissue plasminogen activator. Biochem J 1990; 265: 109-113.
10. Alessi MC, Declerck PJ, De Mol M, Nelles L, Collen D. Purification and characterization of natural and recombinant human plasminogen activator inhibitor-1 (PAI-1). Eur J Biochem 1988; 175: 531-540.
11. Lawrence DA, Strandberg L, Grundstrom T, Ny T. Purification of active human plasminogen activator inhibitor-1 from Escherichia coli. Comparison with natural and recombinant forms purified from eucaryotic cells. Eur J Biochem 1989; 186: 523-533.
12. Mottonen J, Strand A, Symersky J, et al. Structural basis of latency in plasminogen activator inhibitor-1. Nature 1992; 355: 270-273.
13. Hekman CM, Loskutoff DJ. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J Biol Chem 1985; 260: 11581-11587.
14. Declerck PJ, De Mol M, Vaughan DE, Collen D. Identification of a conformationally distinct form of plasminogen activator inhibitor-1, acting as a non-inhibitory substrate for tissue-type plasminogen activator. J Biol Chem 1992; 267: 11693-11696.
15. Urano T, Strandberg L, Johansson LB, Ny T. A substrate-like form of plasminogen activator inhibitor type 1. Conversions between different forms by sodium dodecyl sulphate. Eur J Biochem 1992; 209: 985-992.
16. Munch M, Heegaard CW, Andreasen PA. Interconversions between active, inert and substrate forms of denatured/refolded type-1 plasminogen activator inhibitor. Biochim Biophys Acta 1993; 1202: 29-37.
17. 1-proteinase inhibitor. J Mol Biol 1990; 213: 513-528.
18. Stanssens P, Opsomer C, McKeown YM, Kramer W, Zabeau M, Fritz HJ. Efficient oligonucleotide-directed construction of mutations in expression vectors by the gapped duplex DNA method using alternating selectable markers. Nucleic Acids Res 1989; 17: 4441-4454.
19. Audenaert AM, Knockaert I, Collen D, Declerck PJ. Conversion of plasminogen activator inhibitor-1 from inhibitor to substrate by point mutations in the reactive-site loop. J Biol Chem 1994; 269: 19559-19564.
20. Gils A, Knockaert I, Declerck PJ. Substrate behaviour of plasminogen activator inhibitor-1 is not associated with a lack of insertion of the reactive site loop. Biochemistry 1996; 35: 7474-7481.
21. Verheijen JH, Chang GTG, Kluft C. Evidence for the occurrence of a fast-acting inhibitor for tissue-type plasminogen activator in human plasma. Thromb Haemost 1984; 51: 392-395.
22. Sancho E, Tonge DW, Hockney RC, Booth NA. Purification and characterization of active and stable recombinant plasminogen activator inhibitor (PAI-1) accumulated at high level in Escherichia coli. Eur J Biochem 1994; 224: 125-134.
23. Declerck PJ, Alessi MC, Verstreken M, Kruithof EKO, Juhan-Vague I, Collen D. Measurement of plasminogen activator inhibitor-1 in biological fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 1988; 71: 220-225.
24. Lawrence DA, Olson ST, Palaniappan S, Ginsburg D. Engineering plasminogen activator inhibitor 1 mutants with increased functional stability. Biochemistry 1994; 33: 3643-3648.
25. Berkenpas MB, Lawrence DA, Ginsburg D. Molecular evolution of plasminogen activator inhibitor-1: functional stability. EMBO J 1995; 14: 2969-2977.
26. Tucker HM, Mottonen J, Goldsmith EJ, Gerard RD. Engineering of plasminogen activator inhibitor-1 to reduce the rate of latency transition. Nature Struct Biol 1995; 2: 442-445.
27. Devraj-Kizuk R, Chui DH, Prochownik EV, Carter CJ, Ofosu FA, Blajchman MA. Antithrombin-III-Hamilton: a gene with a point mutation (guanine to adenine) in codon 382 causing impaired serine protease reactivity. Blood 1988; 72: 1518-1523.
28. Perry DJ, Harper PL, Fairham S, Daly M, Carrell RW. Antithrombin Cambridge, 384 Ala to Pro: a new variant identified using the polymerase chain reaction. FEBS Lett 1989; 254: 174-176.
29. Levy NJ, Ramesh N, Cicardi M, Harrison RA, Davis AE. Type II Hereditary angioneurotic edema that may result from a single nucleotide change in the codon for alanine-436 in the C1 inhibitor gene. Proc Natl Acad Sci USA 1990; 87: 265-268.
30. Ireland H, Lane DA, Thompson E, et al. Antithrombin Glasgow II: alanine 382 to threonine mutation in the serpin P12 position, resulting in a substrate reaction with thrombin. Br J Haematol 1991; 79: 70-74.
31. Perry DJ, Daly M, Harper PL, Tait RC, Price J, Walker ID, Carrell RW. Antithrombin Cambridge II, 384 Ala to SER. Further evidence of the role of the reactive centre loop in the inhibitory function of the serpins. FEBS Lett 1991; 285: 248-250.
32. Skriver K, Wikoff WR, Patston PA, Tausk F, Schapira M, Kaplan AP, Bock SC. Substrate properties of Cl inhibitor Ma (alanine 434-glutamic acid). J Biol Chem 1991; 266: 9216-9221.
33. Davis AE, Aulak K, Parad RB, et al. C1 inhibitor hinge region mutations produce dysfunction by different mechanisms. Nat Genet 1992; 1: 354-358.
34. Aulak KS, Eldering E, Hack CE, et al. A hinge region mutation in C1-inhibitor (Ala436→Thr) results in nonsubstrate-like behavior and in polymerization of the molecule. J Biol Chem 1993; 268: 18088-18094.
35. Lawrence DA, Olson ST, Palaniappan S, Ginsburg D. Serpin reactive center loop mobility is required for inhibitor function but not for enzyme recognition. J Biol Chem 1994; 269: 27657-27662.
36. Gils A, Declerck PJ. Proteinase specificity and functional diversity in point mutants of plasminogen activator inhibitor 1. J Biol Chem 1997; 272: 12662-12666.
37. Carrell RW, Evans DL, Stein P. Mobile reactive centre of serpins and the control of thrombosis. Nature 1991; 353: 576-578.
38. Hopkins PCR, Chang WSW, Wardell MR, Stone SR. Inhibitory mechanism of serpins. J Biol Chem 1997; 272: 3905-3909.
39. Wright HT, Blajchman MA. Proteolytically cleaved mutant antithrombin-Hamilton has high stability to denaturation characteristic of wild type inhibitor serpins. FEBS Lett 1994; 348: 14-16.
40. Sancho E, Declerck PJ, Price NC, Kelly SM, Booth NA. Conformational studies on plasminogen activator inhibitor-1 (PAI-1) in active, latent, substrate, and cleaved forms. Biochemistry 1995; 34: 1064-1069.
41. Aertgeerts K, De Ranter CJ, Booth NA, Declerck PJ. Rational design of complex formation between plasminogen activator inhibitor-1 and its target proteinases. J Struct Biol 1997; 118: 236-242.
42. Stratikos E, Gettins PGW. Major proteinase movement upon stable serpin-proteinase complex formation. Proc Natl Acad Sci USA 1997; 94: 453-458.
43. Wilczynska F, Fa M, Karolin J, Ohlsson PI, Johansson LBA, Ny T. Structural insights into serpin-protease complexes reveal the inhibitory mechanism of serpins. Nature Struct Biol 1997; 4: 354-357
44. Plotnick MI, Mayne L, Schechter NM, Rubin H. Distortion of the active site loop of chymotrypsin complexed with a serpin. Biochemistry 1996; 35: 7586-7590.
45. Gettins P, Patston PA, Schapira M. The role of conformational change in serpin structure and function. Bioessays 1993; 15: 461-467.
46. Hood DB, Huntington JA, Gettins PGW. Alpha 1-proteinase inhibitor variant T345R. Influence of P14 residue on substrate and inhibitory pathways. Biochemistry 1994; 33: 8538-8547.